To the authors' knowledge, outcomes and prognostic tools have yet to be clearly defined in patients with metastatic renal cell carcinoma (mRCC) who are treated with immuno-oncology (IO) checkpoint inhibitors (programmed death-ligand 1 [PD-L1] inhibitors).
SAN FRANCISCO, CA USA (UroToday.com) - Dr. Jenny J. Ko presented her study utilizing the IMDC model to predict prognosis in patients undergoing second-line targeted therapy for metastatic RCC.
Vascular endothelial growth factor (VEGF)-targeted therapies are standard treatment for metastatic renal cell carcinoma (mRCC); however, toxicities can lead to drug discontinuation, which can affect patient outcomes.
Login to update email address, newsletter preferences and use bookmarks.
Email
Password
